Cosmo Pharmaceuticals N.V. (CMOPF)
USD 55.0
(0.0%)
USD 55.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 553.98 Million EUR | -31.7% |
| 2022 | 811.08 Million USD | -11.35% |
| 2021 | 914.9 Million USD | 25.43% |
| 2020 | 729.43 Million USD | 11.05% |
| 2019 | 656.84 Million USD | -8.17% |
| 2018 | 715.25 Million EUR | 19.61% |
| 2017 | 597.96 Million EUR | 27.84% |
| 2016 | 467.75 Million EUR | -1.68% |
| 2015 | 475.73 Million EUR | 110.86% |
| 2014 | 225.62 Million EUR | -7.15% |
| 2013 | 243 Million EUR | 60.03% |
| 2012 | 151.84 Million EUR | 94.58% |
| 2011 | 78.03 Million EUR | -15.01% |
| 2010 | 91.82 Million EUR | 28.49% |
| 2009 | 71.46 Million EUR | 23.72% |
| 2008 | 57.76 Million EUR | 22.31% |
| 2007 | 47.22 Million EUR | 86.73% |
| 2006 | 25.29 Million EUR | -10.35% |
| 2005 | 28.21 Million EUR | 20.24% |
| 2004 | 23.46 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 638.25 Million EUR | 15.21% |
| 2024 Q2 | 638.25 Million EUR | 0.0% |
| 2023 Q2 | 803.1 Million USD | 9.0% |
| 2023 FY | 553.98 Million EUR | -31.7% |
| 2023 Q1 | 736.81 Million EUR | -9.16% |
| 2023 Q3 | 553.98 Million EUR | -31.02% |
| 2023 Q4 | 553.98 Million EUR | 0.0% |
| 2022 Q4 | 811.08 Million USD | 6.78% |
| 2022 FY | 811.08 Million USD | -11.35% |
| 2022 Q1 | 846.61 Million EUR | 5.1% |
| 2022 Q2 | 801.01 Million EUR | -5.39% |
| 2022 Q3 | 759.59 Million EUR | -5.17% |
| 2021 Q1 | 659.74 Million EUR | 10.66% |
| 2021 FY | 914.9 Million USD | 25.43% |
| 2021 Q2 | 562.75 Million EUR | -14.7% |
| 2021 Q3 | 933.01 Million EUR | 65.79% |
| 2021 Q4 | 805.56 Million EUR | -13.66% |
| 2020 Q4 | 596.16 Million EUR | -14.72% |
| 2020 FY | 729.43 Million USD | 11.05% |
| 2020 Q2 | 596.61 Million EUR | -9.26% |
| 2020 Q3 | 699.06 Million EUR | 17.17% |
| 2020 Q1 | 657.5 Million EUR | 12.36% |
| 2019 Q3 | 637.84 Million EUR | 7.25% |
| 2019 FY | 656.84 Million USD | -8.17% |
| 2019 Q1 | 667.11 Million EUR | 6.62% |
| 2019 Q2 | 594.73 Million EUR | -10.85% |
| 2019 Q4 | 585.16 Million EUR | -8.26% |
| 2018 FY | 715.25 Million EUR | 19.61% |
| 2018 Q3 | 726.35 Million EUR | 51.45% |
| 2018 Q2 | 479.58 Million EUR | -18.82% |
| 2018 Q1 | 590.77 Million EUR | 18.63% |
| 2018 Q4 | 625.68 Million EUR | -13.86% |
| 2017 Q4 | 497.97 Million EUR | -15.39% |
| 2017 Q2 | 507.26 Million EUR | -6.27% |
| 2017 Q1 | 541.19 Million EUR | 22.04% |
| 2017 FY | 597.96 Million EUR | 27.84% |
| 2017 Q3 | 588.55 Million EUR | 16.03% |
| 2016 Q4 | 443.47 Million EUR | -10.97% |
| 2016 Q2 | 452.61 Million EUR | -12.19% |
| 2016 Q1 | 515.47 Million EUR | 17.7% |
| 2016 FY | 467.75 Million EUR | -1.68% |
| 2016 Q3 | 498.14 Million EUR | 10.06% |
| 2015 Q2 | 450.47 Million EUR | -6.91% |
| 2015 FY | 475.73 Million EUR | 110.86% |
| 2015 Q4 | 437.94 Million EUR | -10.39% |
| 2015 Q3 | 488.74 Million EUR | 8.5% |
| 2015 Q1 | 483.93 Million EUR | 114.49% |
| 2014 FY | 225.62 Million EUR | -7.15% |
| 2014 Q4 | 225.62 Million EUR | -20.76% |
| 2014 Q3 | 284.74 Million EUR | 43.08% |
| 2014 Q2 | 199.01 Million EUR | -27.42% |
| 2014 Q1 | 274.21 Million EUR | 12.84% |
| 2013 Q3 | 328.89 Million EUR | 58.63% |
| 2013 FY | 243 Million EUR | 60.03% |
| 2013 Q4 | 243 Million EUR | -26.11% |
| 2013 Q2 | 207.33 Million EUR | -21.95% |
| 2013 Q1 | 265.66 Million EUR | 74.96% |
| 2012 Q4 | 151.84 Million EUR | 0.0% |
| 2012 Q2 | 123.78 Million EUR | 0.0% |
| 2012 FY | 151.84 Million EUR | 94.58% |
| 2011 Q2 | 91.68 Million EUR | 0.0% |
| 2011 FY | 78.03 Million EUR | -15.01% |
| 2011 Q4 | 78.03 Million EUR | 0.0% |
| 2010 Q2 | 92.46 Million EUR | 0.0% |
| 2010 Q4 | 91.82 Million EUR | 0.0% |
| 2010 FY | 91.82 Million EUR | 28.49% |
| 2009 FY | 71.46 Million EUR | 23.72% |
| 2009 Q4 | 71.46 Million EUR | 0.0% |
| 2008 FY | 57.76 Million EUR | 22.31% |
| 2007 FY | 47.22 Million EUR | 86.73% |
| 2006 FY | 25.29 Million EUR | -10.35% |
| 2005 FY | 28.21 Million EUR | 20.24% |
| 2004 FY | 23.46 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AstraZeneca PLC | 100.97 Billion USD | 99.451% |
| Bristol-Myers Squibb Company PFD CONV 2 | 95.15 Billion USD | 99.418% |
| CSPC Pharmaceutical Group Limited | 6.52 Billion USD | 91.509% |
| Clarus Therapeutics Holdings, Inc. | 51.7 Million USD | -971.362% |
| Novartis AG | 99.94 Billion USD | 99.446% |
| PT Kalbe Farma Tbk. | 1.75 Billion USD | 68.501% |